BACKGROUND
Evidence of hepatic steatosis by imaging, in the absence of secondary causes of hepatic fat accumulation such as viral hepatitis, significant alcohol consumption, use of steatogenic medications, or hereditary disorders; suggests the presence of nonalcoholic fatty liver disease (NAFLD). 1 The reported prevalence of NAFLD varies widely depending on the population studied and modality of diagnosis. The prevalence of NAFLD defined by ultrasound ranged from 17% to 46% worldwide. However, the prevalence of nonalcoholic steatohepatitis (NASH), a histologic subtype of NAFLD, remains relatively lower than that of nonalcoholic fatty liver. Studies regarding NASHrelated cirrhosis remain scarce and its prevalence not well studied. 1, 2 Some of the common risk factors associated with the development of NAFLD include metabolic syndrome (MetS), obesity, diabetes, and dyslipidemia. The prevalence can exceed 65% among individuals with metabolic abnormalities. 2 The exact mechanisms underlying the development of NAFLD in individuals with metabolic abnormalities remain unknown. Individuals with cryptogenic cirrhosis, now considered as "burned out NASH," also exhibit significantly higher prevalence of type II diabetes mellitus, obesity, and dyslipidemia. 3, 4 Most studies conducted in The United States reported NAFLD prevalence rate of around 10% to 35%. Previous studies have indicated higher prevalence among high-risk groups but most of these studies suffered from small sample size. 2 Although imaging tests such as ultrasound do not accurately predict steatohepatitis in patients with NAFLD, its use in individuals with MetS may be useful in identifying individuals who might benefit from diagnostic and prognostic liver biopsy, as MetS is a strong predictor of steatohepatitis. 1, 5 Furthermore, ultrasonographic evidence of hepatic steatosis, combined with other noninvasive methods such as NAFLD fibrosis score, 6 improves diagnostic and prognostic yield. The aim of this study is to determine the prevalence of NAFLD defined by ultrasonography, as well as the rate of advanced fibrosis using NAFLD fibrosis score, in the United States population stratified by different baseline metabolic abnormalities.
METHODS
The Third National Health and Nutrition Examination Survey (NHANES III) was conducted in the United States from 1988 through 1994 by the National Center for Health Statistics, Centers for Disease Control and Prevention to obtain information regarding health and nutrition status of The United States general population. It used complex, multistage, stratified, clustered samples of civilian from 2 months age and above. The survey included interviews questionnaires, standardized physical examination, and laboratory tests from blood samples collected at examination centers and analyzed at central laboratory. NHANES III was approved by the Center for Disease Control and Prevention's Institutional Review board. Further information regarding survey design and sampling methods are available elsewhere. 7 
Study Cohort
During the survey period, 33,199 subjects participated. In total, 16,115 subjects who were 20 to 74 years old completed liver ultrasound examination. Only those liver ultrasound findings reported at "confident or absolute confident levels" were included (N = 12,915). We excluded subjects with chronic hepatitis B, chronic hepatitis C, and excessive alcohol use or elevated transferrin level >50% (N = 1642). In addition, those who were taking medications that might cause hepatic steatosis, 1 such as antiarrhythmic (amiodarone), antineoplastic-antimetabolites (methotrexate), antineoplastic-hormonal (tamoxifen), adrenal corticosteroids (corticosteroids), anticonvulsants (valproate), and antivirals (antiretroviral medicines) (N = 113) were also excluded. The remaining 11,674 adults constituted our study cohort.
Variables and Definitions
Information on demographic characteristics, education and income level, cigarettes and alcohol use was obtained in a household interview. Smoking status was categorized into current and past users. Current smoker was defined as history of ongoing smoking with or without >100 cigarettes in lifetime. Excessive alcohol consumption was defined as an average >21 drinks per week in men and >14 drinks per week for women. 1 The average alcohol consumption was determined based on the 2 survey question responses that queried about the number of days of drinking and the number of drinks on a given drinking day over the past 12-month period.
During the physical examination, individual's body weight, height, and waist to hip ratio were measured. The body mass index (BMI) was calculated and individuals with BMIZ30 kg/m 2 were considered to be obese. Individuals with fasting plasma glucose of Z126 mg/dL or random plasma glucoseZ200 mg/dL, use of oral hypoglycemic medications or insulin, and previous history of diabetes were considered to have diabetes. 8 The presence of MetS was defined based on the guidelines proposed by Third Report of the National Cholesterol Education Program Adult Treatment Panel (ATP III). 9 The ATP III clinical definition of the MetS requires the presence of Z3 of the following abnormalities: (1) waist circumference >102 cm in men and >88 cm in women; (2) a triglyceride level Z150 mg/dL; (3) high-density lipoprotein (HDL) level <40 mg/dL in men and <50 mg/dL in women, (4) systolic blood pressure Z130 mm Hg or diastolic pressure Z85 mm Hg; and (5) fasting plasma glucose Z110 mg/dL. Subjects with MetS were further trichotomized depending on the number of abnormalities of MetS components (3, 4, or 5 metabolic abnormalities). Elevated serum transaminases were defined as ALT > 40 U/L in men and >31 U/L in women, or AST > 37 U/L in men and >31 U/ L in women. 7 Controls were those without any evidence of metabolic abnormalities.
Ultrasonographic Data
The ultrasound examinations were performed in subjects who were 20 to 74 years old using Toshiba Sonolayer SSA-90A and Toshiba video recorder during the study period from 1988 to 1994. The gallbladder ultrasound examinations were performed using standardized procedures to ensure consistency, reliability, and accurate results. 10 During 2009 to 2010, these archived gallbladder ultrasound video images were rereviewed for assessment and grading of hepatic steatosis. Three ultrasound readers were trained by a board-certified radiologist (specialized in hepatic imaging) for assessment of hepatic steatosis using standardized reading protocols. For quality assurance and quality control, a radiologist with 21 years of experience in the interpretation of ultrasound images validated the readers throughout the study period. The liver was graded as normal, mild, moderate, or severe hepatic steatosis based on following information: (1) the presence of liver-to-kidney contrast, (2) the degree of the brightness of liver parenchyma, (3) presence of deep beam attenuation, (4) presence of echogenic walls in the small intrahepatic vessels, and (5) the definition of the gallbladder walls. Further details regarding ultrasound examinations are provided in the supplementary data (Supplemental Digital Content 1, http://links.lww.com/JCG/A278) and are described elsewhere. 10 According to the NHANES manual, the interrater reliability between readers for 4 levels grading (normal, mild, moderate, and severe) of hepatic steatosis had only 75% agreement (k, 0.58), whereas interrater reliability between readers for recoded dichotomous hepatic steatosis (normal/mild and moderate/severe) had 88.7% agreement (k, 0.70). Further, the NHANES ultrasound user analytic manual also recommended users to use recoded dichotomous variable for assessment of hepatic steatosis for analyses. 3 On the basis of this reason and the studies by others, [11] [12] [13] only those subjects with the ultrasonographic findings of moderate or severe hepatic steatosis were considered to have NAFLD in our study.
NAFLD Fibrosis Score
For prediction of advanced fibrosis in individuals with NAFLD, we used the NAFLD fibrosis score which is based on age, BMI, impaired fasting glucose or diabetes, platelet count, albumin, and aspartate aminotransferase and alanine aminotransferase ratio. 6 The score of >0.676 was considered as advanced fibrosis while that of < À 1.455 were considered to have no advanced fibrosis. Score of À1.455 to 0.676 was considered as indeterminate.
Statistical Analysis
The prevalence of NAFLD was estimated for overall study cohort, and for those with or without MetS. The prevalence were weighted to represent the total US population estimates and to account for unequal selection probabilities from the study design and complexity of survey data. Basic descriptive statistics for study population were described using both unweighted frequencies and weighted percentage. They were reported as mean, SDs, and respective 95% confidence interval (CI).
Individuals with metabolic abnormalities were compared with controls using appropriate comparison tests including w 2 test and student t test accounted for the sample weights. Forward stepwise logistic regression method was used to identify independent predictors of NAFLD. Variables with P < 0.05 were considered significant and were added in the final logistic model. The associations were reported as adjusted odds ratios (aORs) (adjusted for age, sex, race, smoking, alcohol use, and education level).
Comparison of an individual metabolic abnormality with controls using multivariate model was further adjusted for other metabolic abnormalities to control for the confounding effects on hepatic steatosis. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics of study participants (n = 11,674) showed a mean age of 42.1 years, 46.2% male, 76% non-Hispanic white, and 28.4% current smokers. The details demographic and baseline characteristics are provided in Table 1 .
Prevalence and Demographic Predictors of NAFLD Diagnosed in the US Population
The prevalence of NAFLD among US population was 18.2% (95% CI, 16.5%-19.9%). Older individuals (60 to 74 y), males, Mexican Americans, and those with lower education were found to have higher prevalence of NAFLD (Table 1) . Multivariate analysis confirmed the following baseline characteristics to be independent predictors of NAFLD; male: aOR = 1.52 (95% CI, 1.32-1.75); Mexican American compared with non-Hispanic white: aOR = 1.62 (95% CI, 1.27-2.06); and less than high school education: aOR = 1.51 (95% CI, 1.25-1.82).
Prevalence of MetS in the US Population
The prevalence of MetS in our cohort was 21% [1715 with 3 metabolic abnormalities (MetS3), 862 with 4 (MetS4), and 240 with 5 abnormalities (MetS5)]. The detailed characteristics of individuals with metabolic abnormalities compared with controls are outlined in Table 2 .
Levels of Transaminases and NAFLD Fibrosis Scores Among Subjects With NAFLD
Only 15% of subjects with NAFLD had elevated serum transaminases using the reference cutoff. The NAFLD fibrosis score was calculated among 1468 with moderate to severe steatosis from the ultrasonography. Of these, 6.6% had advanced fibrosis, 60% had no fibrosis, and 33.6% were in indeterminate range. We also performed a separate analyses for NAFLD fibrosis score by including individuals with mild steatosis. The results are shown in supplementary 
Prevalence of NAFLD in Individuals With MetS
The prevalence of NAFLD among individuals with MetS (n = 2817) was 43% and significantly higher than controls without MetS (aOR, 11.5; 95% CI, 8.9-14.7; Table 3 ). Of these, 24% had moderate steatosis; while 19% had severe steatosis. A total of 20% of NAFLD subjects with MetS had elevated transaminases. Further, we found that the prevalence of NAFLD among subjects with MetS increased with the number of metabolic abnormalities (37%, 49%, and 67% for those with MetS3, MetS4, and MetS5, respectively, Table 3 ). The prevalence of severe steatosis was also increased with higher metabolic abnormalities; 16%, 20%, and 35% for subjects with MetS3, MetS4, and MetS5, respectively (P < 0.001, Fig. 1 ). Among patients with MetS, 11% already had advanced fibrosis at the time of NAFLD diagnosis (Table 4) . When compared with controls, NAFLD subjects with MetS were older (51.0 vs. 35.6 y, P < 0.001) and had lower education (31.0% vs. 15.1%, P < 0.001). There was no gender and racial difference between both groups ( Table 2) . 
Prevalence of NAFLD Based on the Individual Component of MetS in the US Population

NAFLD in Individuals With Increased Waist Circumference
The prevalence of NAFLD in subjects with increased waist circumference was 31% and it was significantly higher than that in controls with normal waist circumference (6%, P < 0.001, Table 3 ). Of these, 17% had elevated serum transaminases, and 8.7% had advanced fibrosis (Tables 3,  4 ). In comparison with controls, NAFLD individuals with increased waist circumference were older (47.1 vs. 35.6 y, P < 0.001), predominantly female (64.1% vs. 53.8%, P < 0.001), and less educated (27.1% vs. 15.1%, P < 0.001, Table 2 ).
NAFLD in Individuals With Impaired Fasting Glucose/Diabetes
The prevalence of NAFLD in subjects with impaired fasting glucose/diabetes was 41% and is significantly higher than that of controls (6%, P = 0.007, Table 3 ). Of these, 20% had elevated serum transaminases, and 18% had advanced fibrosis (Tables 3, 4 ). In comparison with controls, NAFLD subjects with impaired fasting glucose were older (53.7 vs. 35.6 y, P < 0.001) and had lower education (34.9% vs. 15.1%, P < 0.001). However, both groups did not differ significantly with regards to sex, race, smoking, or alcohol use (Table 2) .
NAFLD in Individuals With High Triglyceride and Low HDL Levels
The prevalence of NAFLD in subjects with high triglyceride and low HDL level was 35% and 28%, respectively. However, the prevalence of advanced fibrosis in those with high triglyceride and low HDL was identical (8%, Tables 3, 4). Both conditions were independent predictors of NAFLD after adjusting for other metabolic abnormalities [high triglyceride (aOR, 2.2; 95% CI, 1.5-3.0) and low HDL (aOR, 1.5; 95% CI, 1.2-1.9), Table 3 ].
NAFLD in Individuals With High Blood Pressure
The prevalence of NAFLD in subjects with high blood pressure was 29%. Of these, 18% had elevated serum transaminases, and 11% had advanced fibrosis (Tables 3,  4) . Despite the high prevalence of NAFLD among subjects with high blood pressure compared with controls (29% vs. 6%), high blood pressure was not an independent predictor of NAFLD (aOR, 1.3; 95% CI, 0.9-1.8; Table 3 ) in the multivariate analysis.
Prevalence of NAFLD in US Population Without Metabolic Abnormalities
The prevalence of NAFLD in the absence of the MetS and any of its individual components was 6%. Of these, 5% and 1.5% had moderate and severe steatosis, respectively. The detailed demographics of these subjects are provided in Table 5 . In the multivariate model, only Mexican American race (compared with non-Hispanic white) was found to be an independent predictor for NAFLD in subjects without any components of metabolic abnormalities (aOR, 2.1; 95% CI, 1.3-3.4).
DISCUSSION
We and others have reported the high occurrence of NAFLD among subjects with MetS. 4, 14 In this study, we provide several novel findings with clinical relevance regarding the association between MetS and its individual component and the presence of NAFLD using the ultrasonography and its severity as measured by NAFLD fibrosis score. Several pertinent findings in our study are (i) the prevalence of NAFLD among subjects with MetS increased with the number of metabolic abnormalities and it exceeds 65% in those with all 5 abnormalities, (ii) subjects with higher numbers of metabolic abnormalities tend to have higher prevalence of advanced fibrosis at the time of NAFLD diagnosis, (iii) several individual components of MetS, notably, increased waist circumference, impaired fasting glucose and dyslipidemia, are independent predictors of NAFLD, and (iv) NAFLD is also prevalent among subjects without any metabolic abnormalities especially in those with Mexican American descent.
Current NAFLD guidelines recommend the use of the NAFLD fibrosis score and the presence of MetS to identify individuals who might benefit from liver biopsy. 1 Our study provided the objective evidence in support of this recommendation. We observed a significantly higher risk of Table 3 ). The prevalence of NAFLD and the presence of advanced fibrosis increased substantially with the increase in the number of metabolic abnormalities ( Fig. 1 and Tables 3, 4) . Our results suggest the possibilities of the synergistic effects of different metabolic abnormalities on the pathogenesis and the progression of NAFLD.
Our results attest the notion that the levels of serum transaminases should not be used as the screening tests for the presence of underlying NAFLD in those who are at risk. Only 15% to 20% of subjects with NAFLD had abnormal transaminases in our study. We suggest that the presence of any metabolic abnormalities should prompt the health care providers to further investigate the possibilities of NAFLD in these subjects, despite serum transaminases are within the normal range.
Apart from metabolic abnormalities, we also found age, sex, and race as independent predictors of NAFLD. Others have reported the gender and racial differences in patients with NAFLD. 1 We found the higher prevalence of NAFLD in Mexican Americans compared with nonHispanic white. Interestingly, Mexican-American descent is the only factor independently associated with NAFLD among subjects without metabolic abnormalities (Table 5) . It is plausible that underlying genetic variation plays an important role for the racial differences in NAFLD susceptibility. This notion is supported by the recent discovery of the I148M polymorphism of patatin-like phospholipase domain-containing 3 (PNPLA3), which influences hepatic triglycerides accumulation and the susceptibility to fibrosis. This allele is found to be most prevalent in Hispanic compared with other ethnicities. 2, 15, 16 It is well known that NAFLD is part of the spectrum of the MetS. 1, 14 However, our study reveals that the risk of NAFLD, in fact, is increased in subjects who have abnormalities in any components of the metabolic syndrome, except for high blood pressure ( Fig. 2 and Table 3 ). Hepatic steatosis was found in 41% of subjects with impaired fasting glucose or diabetes and at the time of the diagnosis B18% already had advanced fibrosis, based on NAFLD fibrosis scores. Our findings are of importance as the prevalence of metabolic abnormalities has increased dramatically in the United States since NHANES III was conducted. Undoubtedly, this might have led to an even higher prevalence of NAFLD in the US population than that reported using NHANES III. Current practice guidelines suggested that liver biopsy should be performed among suspected NAFLD with MetS and those with advanced fibrosis by NAFLD fibrosis score. This may lead to B10% of US population between ages 20 and 74 years old requiring liver biopsy based on our study results. This number might be significantly higher as the prevalence of MetS has increased from B28% in 1988 to 1994 to B34% in 1999 to 2006. 17 Undeniably, this will have significant financial impact on the health care system. Considering significantly high risk of NAFLD and advanced fibrosis among subjects with any metabolic abnormalities, future studies to determine the cost effectiveness of noninvasive methods for identifying NAFLD among these subjects are warranted.
We acknowledge several limitations of our study. First, NHANES III database does not provide histologic data that limited us to further categorize NAFLD by histologic subtypes and evaluating its association with metabolic abnormalities. Second, our results might not be applicable to specific populations such as homeless, institutionalized, and incarcerated individuals; which were not part of the NHANES survey. Third, we may not be able to exclude rare hereditary syndromes which account for small fraction of individuals with hepatic steatosis due to the unavailability of dataset. Fourth, some degree of recall bias may have been present while evaluating for alcohol consumption or medication use from NHANES III questionnaire. Fifth, the reported sensitivity of NAFLD fibrosis score to predict fibrosis is around 67%. Therefore, we in fact might underestimate the true prevalence of advanced fibrosis among NAFLD subjects in our study. Sixth, the ultrasound is not the most sensitive method to characterize steatosis or diagnose NAFLD but it is the most practical test for large population-based study when obtaining liver biopsy in these subjects is not feasible. Lastly, it is important to note that the interrater reliability for 4-level steatosis grading had k of 0.58 which is considered as weak reliability. 10 This may affect our ability to accurately estimate fibrosis in various groups.
In conclusion, our study suggests a significantly high prevalence of NAFLD among individuals with the MetS and its individual components in the US population. Further well-designed, prospective, long-term, outcome-based studies among these high-risk groups will provide further insight on the disease process and will definitely aid in clinical care.
